Table 1.
Comparison of baseline characteristics of patients with compensated advanced chronic liver disease (cACLD) with vs without hepatic decompensation during follow‐up
| cACLD patients, n = 292 | Without first hepatic decompensation, n = 267 | With first hepatic decompensation, n = 25 | P‐value | |
|---|---|---|---|---|
| Sex, male/female (% male) | 190/102 (65%) | 176/91 (66%) | 14/11 (56%) | 0.320 |
| Age, yr | 54 ± 12 | 54 ± 12 | 57 ± 12 | 0.197 |
| BMI, kg/m2 | 27 ± 6 | 28 ± 6 | 26 ± 5 | 0.177 |
| Aetiology | ||||
| Viral hepatitis, n (%) | 195 (67) | 181 (68) | 14 (56) | 0.097 |
| (N)AFLD, n (%) | 43 (15) | 40 (15) | 3 (12) | |
| Other, n (%) | 38 (13) | 34 (13) | 4 (16) | |
| Cryptogenic, n (%) | 16 (5) | 12 (4) | 4 (16) | |
| Diabetes, n (%) | 59 (20) | 51 (19) | 8 (32) | 0.125 |
| Fasting glucose, mg/dL | 107 ± 23 | 106 ± 22 | 112 ± 32 | 0.611 |
| Triglycerides, mg/dL | 115 ± 71 | 116 ± 71 | 99 ± 72 | 0.245 |
| Total cholesterol, mg/dL | 162 ± 52 | 164 ± 52 | 144 ± 40 | 0.066 |
| Statin treatment, n (%) | 26 (9) | 22 (8) | 4 (16) | 0.383 |
| INR | 1.2 ± 0.3 | 1.2 ± 0.3 | 1.3 ± 0.3 | 0.095 |
| Albumin, g/L | 42 ± 4 | 42 ± 4 | 37 ± 5 | <0.001 |
| MELD‐Na score, points | 9.4 ± 3.3 | 9.1 ± 3.2 | 12.2 ± 3.9 | 0.001 |
| Liver stiffness, median kPa (range) | 18 (12‐28) | 17 (12‐26) | 26 (21‐47) | 0.001 |
| CAP, dB/m | 265 ± 63 | 266 ± 64 | 246 ± 59 | 0.126 |
| HVPG, median mm Hg (range)a | 14 (9‐19) | 13 (8‐18) | 17 (11‐22) | 0.156 |
| CSPH, n (%)a | 60 (70) | 50 (68) | 10 (77) | 0.746 |
BMI, body mass index; CAP, controlled attenuation parameter; cACLD, compensated advanced chronic liver disease; CSPH, clinically significant portal hypertension; HVPG, hepatic venous pressure gradient; INR, international normalized ratio; MELD‐Na, model for end‐stage liver disease including sodium; (N)AFLD, (non)alcoholic fatty liver disease.
Statistically significant P‐values are shown in bold.
a
Data were available in 86 patients (n = 73 without decompensation and n = 13 with decompensation).